The round was led by new investor Dell Technologies Capital, the venture arm of Dell Technologies, with participation from existing investors Qualcomm Ventures, Axon Ventures and life sciences industry executive Greg Lucier.
The company intends to use the funds to expand market adoption and product development of its DRAGEN™ platform.
Led by Pieter van Rooyen, Ph.D., chief executive officer, Edico Genome provides DRAGEN, an automated solution for analysis of next-generation sequencing data both onsite and in the cloud, which is powered by FPGA-centric technology that features optimized algorithms for mapping, alignment, sorting, variant calling and more to enable a whole genome to be analyzed in only 20 minutes on-site, or under 10 minutes in a single cloud instance.
Customers include top clinical and academic research institutions and high-throughput sequencing centers.
FinSMEs
09/05/2017